Tiara cases update: Today Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX:NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that an original article was published in Circulation: Cardiovascular Interventions titled ‘Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement’, which reports for the first time ever the experience of transcatheter mitral valve replacement (“TMVR”) using Neovasc’s Tiara™ (“Tiara”) valve in patients with previous aortic valve replacement. The Tiara is a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of the most prevalent valvular heart diseases in western countries. Tiara is not currently approved for commercial sale in any geographies.
The article describes the periprocedural and short-term outcomes of patients with severe MR and previous surgical aortic valve prosthesis replacement treated with the Tiara. The article describes procedural success rate of 100% with no death, myocardial infarction, stroke, major bleeding, or access site complications at 30 days. In addition, MR was eliminated in patients immediately after implantation. The authors of the article conclude that, “transapical mitral valve replacement with the Tiara valve in high-risk patients with severe MR and aortic valve prostheses is technically feasible and can be performed safely.” The article is currently available for download at the American Heart Association Journals website, https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.006412
The editorial comment titled ‘Taking Transcatheter Mitral Valve Replacement to the Next Level’ written by Mayra Guerrero and Charanjit Rihal concludes that: “The investigators, are taking the field of TMVR to the next level where both prosthetic aortic valves and transcatheter mitral prosthesis coexist, and should be congratulated for their contribution.” The article is currently available for download at the American Heart Association Journals website, https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.007369.